Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,629 GBX | -0.67% | -7.78% | +12.33% |
12:02am | US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59 | RE |
Jun. 07 | GSK says FDA Approves Expanded Age Indication For Arexvy, RSV Vaccine For Adults Aged 50-59 At Increased Risk | RE |
- Stock Market
- Equities
- GSK Stock
- News GSK plc
- Transcripts